BETAMETHASONE DIPROPIONATE USP, 0.05%- betamethasone dipropionate usp, 0.05% ointment Tasman Pharma Inc.


Betamethasone Dipropionate Ointment USP, 0.05%

(Potency expressed as betamethasone) Rx only

FOR DERMATOLOGIC USE ONLY. NOT FOR OPHTHALMIC USE.

DESCRIPTION

Betamethasone dipropionate ointment contains betamethasone dipropionate USP, a synthetic adrenocorticosteroid, for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity. Betamethasone dipropionate is a white to cream white odorless crystalline powder insoluble in water. Chemically, it is 9-fluoro-11 β ,17,21-trihydroxy-16 β -methylpregna-1,4-diene-3,20-dione 17,21- dipropionate. The structural formula is:



Molecular Formula: C28H37FO7

Molecular Weight: 504.60

Each gram of the 0.05% ointment contains 0.64 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone) in an ointment base of mineral oil and white petrolatum.

CLINICAL PHARMACOLOGY

Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man (See **DOSAGE AND ADMINISTRATION**).

Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is

determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (See **DOSAGE AND ADMINISTRATION**).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

INDICATIONS AND USAGE

Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

PRECAUTIONS

GENERAL

Systemic absorption of topical corticosteroids has produced reversible hypothalamic pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings (See **DOSAGE AND ADMINISTRATION**).

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See **PRECAUTIONS—Pediatric Use**). If irritation develops, topical corticosteroids should be discontinued, and appropriate

therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

INFORMATION FOR PATIENTS

Patients using topical corticosteroids should receive the following information and instructions:

- 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
- 2. Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.
- 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive.
- 4. Patients should report any signs of local adverse reactions.
- 5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings (See **DOSAGE AND ADMINISTRATION**).

LABORATORY TESTS

The following tests may be helpful in evaluating HPA axis suppression:

Urinary free cortisol test ACTH stimulation test

CARCINOGENESIS, MUTAGENESIS AND IMPAIRMENT OF FERTILITY

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

PREGNANCY

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

NURSING MOTHERS

It is not known whether topical administration of corticosteroids could result in sufficient

systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities **not** likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

PEDIATRIC USE

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid- induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

ADVERSE REACTIONS

The following local adverse reactions are reported infrequently when betamethasone dipropionate ointment is used as recommended in the **DOSAGE AND ADMINISTRATION** section. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infections, skin atrophy, striae and miliaria.

Systemic absorption of topical corticosteroids has produced reversible hypothalamicpituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia and glucosuria in some patients.

OVERDOSAGE

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See **PRECAUTIONS**).

DOSAGE AND ADMINISTRATION

Apply a thin film of betamethasone dipropionate ointment to the affected skin areas once daily. In some cases, twice daily dosage may be necessary.

If an infection develops, appropriate antimicrobial therapy should be instituted.

Betamethasone dipropionate ointment should not be used with occlusive dressings.

HOW SUPPLIED

Betamethasone dipropionate ointment USP, 0.05% is supplied as follows:

15 g tubes NDC 72641-004-15

45 g tubes NDC 72641-004-45

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light and freezing.

Manufactured For:

Tasman Pharma Inc.

Warminster, PA 18974

Made in Canada.

Rev. 04/2021.

C-A231

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 72641-004-45

Betamethasone Dipropionate Ointment USP, 0.05% (**Potency expressed as Betamethasone**) FOR DERMATOLOGIC USE ONLY.

NOT FOR OPHTHALMIC USE.

45 g Rx only



BETAMETHASONE DIPROPIONATE USP, 0.05%

Product Infor	mation							
Product Type		HUMAN PRESCRIPTION DR	RUG	ltem Co	ode (Sou	ırce)	NDC:7	72641-004
Route of Admin	istration	TOPICAL						
Active Ingred	ient/Active	Moiety						
						of Strength St		Strength
BETAMETHASONE DIPROPIONATE (UNII: 826Y60901U) (BETAMET UNII:9842X06Q6M)				SONE -	NE - BETAMETHASONE 0.5 m			0.5 mg in 1 g
Inactive Ingre	dients							
Ingredient Name						Strength		
MINERAL OIL (UNII: T5L8T28FGP)								
	: 15L8128FGP)							
		•						
PETROLATUM (UN		,						
PETROLATUM (UN								
PETROLATUM (UN		,						
PETROLATUM (UN Packaging	II: 4T6H12BN9U)	kage Description			ting Sta Date	rt		ting End ate
PETROLATUM (UN Packaging # Item Code	II: 4T6H12BN9U)	kage Description	02		Date	rt		-
PETROLATUM (UN Packaging # Item Code 1 NDC:72641-004- 15	II: 4T6H12BN9U) Pac 1 in 1 CARTON	kage Description		C	Date	rt		-
PETROLATUM (UN Packaging # Item Code 1 NDC:72641-004- 1 NDC:72641- 1 NDC:72641-004- 1 NDC:72641-004- 1 NDC:72641-	II: 4T6H12BN9U) Pac 1 in 1 CARTON 15 g in 1 TUBE	kage Description ; Type 0: Not a Combinati	ion	C	2 2	rt		-
PETROLATUM (UN Particular (UN Partic	II: 4T6H12BN9U) Pac 1 in 1 CARTON 15 g in 1 TUBE Product 1 in 1 CARTON	kage Description ; Type 0: Not a Combinati	ion 02	C 2/18/2022	2 2	rt		-
PETROLATUM (UN Packaging Item Code 1 NDC:72641-004- 1 NDC:72641-004- 2 NDC:72641-004- 45	II: 4T6H12BN9U) Pac 1 in 1 CARTON 15 g in 1 TUBE Product 1 in 1 CARTON 45 g in 1 TUBE	kage Description ; Type 0: Not a Combinati	ion 02	C 2/18/2022	2 2	rt		-
PETROLATUM (UN # Item Code 1 NDC:72641-004- 2 NDC:72641-004- 2	Pac 1 in 1 CARTON 15 g in 1 TUBE Product 1 in 1 CARTON 45 g in 1 TUBE Product	:kage Description E; Type 0: Not a Combinati	ion 02	C 2/18/2022	2 2	rt		-
PETROLATUM (UN Packaging Item Code 1 NDC:72641-004- 1 NDC:72641-004- 2 NDC:72641-004- 45	Pac 1 in 1 CARTON 15 g in 1 TUBE Product 1 in 1 CARTON 45 g in 1 TUBE Product Unformat	:kage Description E; Type 0: Not a Combinati	ion 02	C 2/18/2022 2/18/2022	2 2		D	-

Labeler - Tasman Pharma Inc. (080860172)

Establishment									
Name	Address	ID/FEI	Business Operations						
Halo Pharmaceutical Canada Inc., a subsidiary of Cambrex Corporation.		250928632	ANALYSIS(72641-004), LABEL(72641-004), MANUFACTURE(72641-004), PACK(72641-004)						